Provided by Tiger Fintech (Singapore) Pte. Ltd.

OnKure Therapeutics, Inc.

4.61
-0.0100-0.22%
Post-market: 4.610.00000.00%17:00 EDT
Volume:39.00K
Turnover:178.63K
Market Cap:61.49M
PE:-0.30
High:4.68
Open:4.67
Low:4.45
Close:4.62
Loading ...

Onkure Therapeutics Faces Stiff Competition in the Pharmaceutical Sector: Challenges in Commercializing PI3Ka Therapies

TIPRANKS
·
12 Mar

OnKure Therapeutics Is Maintained at Outperform by Oppenheimer

Dow Jones
·
11 Mar

Oppenheimer Adjusts Price Target on OnKure Therapeutics to $30 From $35, Keeps Outperform Rating

MT Newswires Live
·
11 Mar

Analysts Offer Insights on Healthcare Companies: OnKure Therapeutics (OKUR) and EyePoint Pharmaceuticals (EYPT)

TIPRANKS
·
11 Mar

Onkure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

THOMSON REUTERS
·
11 Mar

Onkure Therapeutics: Expansion of Pi3ka Franchise to Include a Pan-Mutant Selective Program; Development Candidate Expected to Be Announced in Q2 2025

THOMSON REUTERS
·
11 Mar

Press Release: OnKure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Dow Jones
·
11 Mar

OnKure Therapeutics to Present at Upcoming Leerink and Stifel Investor Conferences

GlobeNewswire
·
04 Mar

U.S. RESEARCH ROUNDUP-Apple, Coinbase Global, Nextracker

Reuters
·
29 Jan

Onkure Therapeutics Inc : Jonestrading Initiates Coverage With Buy Rating; Target Price $32

THOMSON REUTERS
·
29 Jan

OnKure Therapeutics Initiated at Buy by Jones Trading

Dow Jones
·
29 Jan

Oppenheimer Remains a Buy on OnKure Therapeutics (OKUR)

TIPRANKS
·
11 Dec 2024

Onkure Therapeutics Inc - No Dose Interruptions, Delays, Reductions, or Discontinuations Reported

THOMSON REUTERS
·
10 Dec 2024

Onkure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (Pk) Data From Its First-in-Human Pikture-01 Trial of Oki-219

THOMSON REUTERS
·
10 Dec 2024

Onkure Therapeutics Inc - Oki-219 Well Tolerated With No Hyperglycemia and Only Grade 1 Traes

THOMSON REUTERS
·
10 Dec 2024

OnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First-In-Human PIKture-01 Trial of OKI-219

GlobeNewswire
·
10 Dec 2024